Previous 10 | Next 10 |
The first five months of the year marked the worst start for the S&P 500 since 1970 ― and the sixth worst back to 1928. Stock valuations have come down, but company earnings remain solid. Earnings will slow, but 20% is hard to imagine, even in a recession. For fur...
How similar will the next three or five years look from the years that immediately preceded the pandemic? And what are the implications for us as global equity investors? We don’t expect anything like the hyperinflation and stagflation we experienced in the 1970s; our outlook s...
As the MOMO, YOLO, and BTFD days sink deeper into the past, we remind investors to focus on fundamentals. Johnson & Johnson’s scale and diversified business greatly reduce the risk generally involved when investing in pharmaceutical stocks heavily dependent on a handful of ...
With the world facing inflationary and geopolitical hurdles, economic growth is poised to slow. Shares across sectors have been hit hard. Investors in growth stocks must identify companies with the right features to overcome headwinds to earnings. For further details see: ...
Healthcare, Staples, and Utilities continue to outperform as selling intensifies in the growth style. Investor positioning is still light in the space – even after a year of alpha. While absolute valuations have turned somewhat pricey, the defensive supersector shows decent...
During the last Fed rate raising cycle, it took the Federal Reserve five years to raise the fed funds rate to 2.50%. The Fed kept rates far too low for far too long and now we are dealing with the consequences. Both fiscal and monetary policy have been highly inflationary, and we are ...
IYH gained 12% during 7 weeks from February 22, and then fell by 9% in the next 3 weeks. IYH posted strong price returns over the medium and long term, but generated 1% yield. Biotechnology and Life Sciences Tools & Services companies historically had cyclical price movements,...
Typically, we look at net new highs as a way to confirm moves in the broader market. At the high last Wednesday, over 90% of S&P 500’s new highs came from defensive sectors. In other words, defensives have been a notable pocket of strength recently. For further de...
Stock markets fell in the first quarter as Russia’s invasion of Ukraine destabilized the growth outlook, amplified concerns about rising interest rates and unleashed geopolitical risks. While the conflict has created many uncertainties, we believe the impact of persistent infla...
The XBI biotech index peaked early last year, and it's now back to where it was in April of 2020. The biopharma stocks got powerfully inflated during 2020 by the pandemic. The biotech stocks are going to need some good news to get moving again. For further details see: B...
News, Short Squeeze, Breakout and More Instantly...
John Hancock Multifactor Healthcare Company Name:
JHMH Stock Symbol:
NYSE Market:
John Hancock Investment Management announces changes to its ETF lineup Canada NewsWire $ unless otherwise stated ...
John Hancock Investment Management celebrates five-year anniversary of its original ETF suite PR Newswire BOSTON, Sept. 28, 2020 TSX/NYSE/PSE: MFC SEHK: 945 BOSTON , Sept. 28, 2020 /PRNewswire/ - John Hancock Investment Managem...
BOSTON , Feb. 5, 2019 /PRNewswire/ -- John Hancock Investments today announced that the expense ratios for its nine sector ETFs subadvised by Dimensional Fund Advisors, LP, its Floating Rate Income Fund subadvised by Bain Capital Credit, and its Small Cap Value Fund subadvised by Wel...